摘要
子宫内膜癌(endometrial cancer,EC)是最常见的妇科恶性肿瘤之一,近年来EC的发病率和死亡率都有上升的趋势,晚期、转移和复发患者预后较差。VEGF(vascular endothelial growth factor)和VEGFR(vascular endothelial growth factor receptor)对肿瘤的生长、浸润、转移及血管生成具有重要作用。目前研究证实靶向VEGF及其受体的抗血管生成药物在多种肿瘤的治疗中均有较好的疗效。分析VEGF及VEGFR的表达与EC患者临床病理特征的关系,有助于推进其对于EC的早期诊断和预后评估的作用。关于靶向VEGF及其受体的药物在EC中的疗效及安全性,相关的临床实验已经开展,但是要得到明确的研究结果还需要更多临床数据支撑,并且此类药物在EC的临床研究应谨慎进行。本综述总结了VEGF及其受体在EC中表达的临床意义、VEGF/VEGFR信号通路的调控机制以及抗血管生成药物靶向治疗的最新研究进展。
Endometrial cancer(EC)is one of the most common gynecologic malignancies.In recent years,the incidence rate and mortality rate of EC have been increasing.The prognosis of endometrial cancer in advanced stage,metastasis and recurrence is poor.Vascular endothelial growth factor(VEGF)and vascular endothelial growth factor receptor(VEGFR)play important roles in tumor growth,invasion,metastasis and angiogenesis.Recent studies have confirmed that anti angiogenesis drugs targeting VEGF and its receptor have good curative effect in the treatment of a variety of tumors.At the same time,analysis of the relationship between the expression of VEGF and VEGFR and the clinicopathological features of EC patients will help to promote its role in the early diagnosis and prognosis evaluation of EC.As for the efficacy and safety of drugs targeting VEGF and its receptor in EC,relevant clinical trials have been carried out.However,more clinical data are needed to obtain clear research results,and clinical studies of such drugs in EC should be carried out with caution.This review summarizes the clinical significance of VEGF and its receptor expression in EC,the regulatory mechanism of VEGF/VEGFR signaling pathway,and the latest research progress of targeted therapy of anti angiogenic drugs.
作者
王昭娣
张云凤
王悦
WANG Zhao-di;ZHANG Yun-feng;WANG Yue(Department of Obstetrics and Gynecology,Henan University People’s Hospital,Henan Provincial People’s Hospital,Zhengzhou 450003,China)
出处
《医药论坛杂志》
2021年第23期139-144,共6页
Journal of Medical Forum
